NEUPOGEN 30 MU Price

Overview

Welcome to Dwaey, specifically on NEUPOGEN 30 MU Injection page.
This medicine contains an important and useful components, as it consists of Filgrastim.
NEUPOGEN 30 MU is available in the market in concentration 300mcg/0.5ml and in the form of Injection.

F. HOFFMANN-LA ROCHE LTD. is the producer of NEUPOGEN 30 MU and it is imported from SWITZERLAND, The most popular alternatives of NEUPOGEN 30 MU are listed downward .

Mode Of Action

Filgrastim is a granulocyte-colony stimulating factor which binds to cell surface receptors on haemetopoietic cells thus stimulating the development of granulocytes to increase their migration and cytotoxicity.

Indication

• Myelosuppressive chemotherapy
• Acute Myeloid Leukemia receiving induction or consolidation chemotherapy
• Peripheral blood progenitor cell collection and therapy
• Severe Neutropenia
• Bone marrow transplantation
• HIV infection.

Precaution

Filgrastim should not be administered within 24 hours before and after chemotherapy. Premalignant or malignant myeloid condition; sickle-cell disease; osteoporotic bone disease; withdraw treatment if there are signs of pulmonary infiltrates. Fluid retention or heart failure. Monitor CBC and platelet count during therapy. Monitor bone density in patients with osteoporosis (long-term treatment). Regular morphological and cytogenic bone-marrow examinations in severe congenital neutropenia. Pregnancy and lactation. Lactation: excretion in milk unknown; use with caution

Side Effects

• >10% Nausea (57%)
• Vomiting (57%)
• Bone pain (22%-33%)
• Alopecia (18%)
• Diarrhea (14%)
• Fever (12%)
• Fatigue (11%) 1-10% Headache
• Anorexia
• Chest pain
• Cough
• Dyspnea
• Constipation
• Stomatitis
• Sore throat
• Rash Frequency Not Defined Elevated uric acid
• Elevated lactate dehydrogenase
• Elevated alkaline phosphatase Potentially Fatal: Pulmonary infiltrates leading to resp failure or acute resp distress syndrome.

Contra indication

Hypersensitivity to E. coli derived proteins, Filgrastim or any component of the product. Myeloid malignancies. Not to be used within 24 hr of cytotoxic chemotherapy admin due to the sensitivity of rapidly dividing myeloid cells. Severe congenital neutropaenia (Kostman's syndrome) with abnormal cytogenetics.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks